Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny From Prosecutors

Executive Summary

Off-label marketing and kickbacks may no longer be the top targets of government healthcare fraud investigations as more companies are being hit with subpoenas for pricing information.


Related Content

Pfizer Agrees To Oversight Of Charitable Assistance Programs In DOJ Settlement
Mylan's EpiPen Nightmare Not Over Yet, But Will Congress Just Write?
Off-Label Convictions Of Device Execs Could Impact Pharma Sales Reps
Pfizer Opioid Marketing Agreement With Chicago Follows Help In Suit Against Other Firms
Acquittal Of Former Warner Chilcott Exec May Make Future Prosecutions More Difficult
Foreign Bribery Investigations Ramping Up, Along With 'Carrot' For Cooperation
Opioid Marketing Settlement: Endo Sales Reps To Become Abuse Watchdogs
Vascular Solutions Not-Guilty Verdict Another Challenge To FDA Off-Label Oversight
Mylan Joins Firms Facing DOJ Probe On Price Hikes; Senate Plans Industry-Free Hearing
The Era Of Billion Dollar Pharma Settlements


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts